唑来膦酸联合经皮椎体后凸成形术治疗绝经后女性单一T12或L1椎体骨质疏松性压缩骨折
本研究为1年前瞻性研究,纳入101例因T12或L1骨质疏松性椎体压缩骨折(OVCF)接受经皮椎体后凸成形术(PKP)的绝经后女性,随机分为唑来膦酸(ZOL)组(n=50)和对照组(n=51)。ZOL组术前静脉输注5 mg唑来膦酸并联合0.25μg/d骨化三醇及D3 600 mg/d碳酸钙治疗一年,对照组仅用相同剂量骨化三醇和碳酸钙D3。结果显示ZOL组在6和12个月时骨密度高于对照组(p<0.01),骨标志物和VAS评分显著低于对照组,无新发骨折,对照组再压缩椎体骨折发生率为11.7%而ZOL组未检出。
要点
- ZOL组6和12个月骨密度高于对照组(p<0.01)。
- ZOL组骨标志物(NMID、P1NP、β-CTX)和VAS评分显著低于对照组。
- 对照组再压缩椎体骨折发生率为11.7%,ZOL组未检出。
核心结论
- 静脉输注唑来膦酸联合PKP有益于治疗T12或L1骨质疏松性椎体压缩骨折。
研究设计与样本
- 1年前瞻性研究,纳入2015年8月至2017年7月在本院接受PKP的101例T12或L1 OVCF绝经后女性,随机分为ZOL组(n=50)和对照组(n=51)。
主要发现
- 两组年龄、身高、体重、BMI、绝经年龄和骨折椎体无统计学显著差异。
- 治疗6和12个月时,ZOL组骨密度高于对照组(p<0.01)。
- ZOL组骨标志物(NMID、P1NP、β-CTX)和VAS评分显著低于对照组。
- ZOL组无新发骨折;对照组再压缩椎体骨折发生率为11.7%,ZOL组未检出。
- ZOL组轻度不良反应显著高于对照组,但均经对症治疗后缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We performed a 1-year prospective study to see whether zoledronic acid infusion combined with percutaneous kyphoplasty could provide more benefits in the treatment of T12 or L1 osteoporotic vertebral compression fracture (OVCF). INTRODUCTION: To investigate and analyze the clinical effects of zoledronic acid (ZOL) in combination with percutaneous kyphoplasty (PKP) in the treatment of OVCF in postmenopausal women. METHODS: Included in this study were 101 postmenopausal women patients with T12 or L1 OVCF who received PKP in our hospital between August 2015 and July 2017. They were randomly assigned to a zoledronic acid (ZOL) group (n = 50) or a control group (n = 51). Patients in ZOL group were treated preoperatively with IV infusion of 5 mg ZOL in combination with 0.25μg/d calcitriol and D3 600 mg/d calcium carbonate for a year. Patients in the control group were treated with the same dose of calcitriol and calcium carbonate D3 without ZOL. RESULTS: There was no statistically significant difference in age, height, weight, body mass index (BMI), menopause age, and the fractured vertebral body between the two groups. At 6 and 12 months after treatment, bone mineral density (BMD) in ZOL group was higher than that in the control group (p < 0.01); bone markers (NMID, P1NP, and β-CTX) and the VAS score in ZOL group were significantly lower than those in the control group. No new fracture occurred in ZOL group. The incidence of recompression vertebral fracture (RVF) in the control group was 11.7%, while no RVF was detected in any patient in ZOL group. Mild adverse reactions in ZOL group were significantly higher than those in the control group, but all of them were relieved after symptomatic treatment. CONCLUSIONS: ZOL IV infusion in combination with PKP is beneficial for the treatment of T12 or L1 OVCF.
引用
- Zhang J, Zhang T, Xu X, et al. Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women. Osteoporos Int. 2019. PMID: 30976888. doi:10.1007/s00198-019-04896-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。